A review of depression in the head and neck cancer patient

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 6, 2009, Pages 397-403

  Lydiatt, William M ^a   Moran, Jessica ^b   Burke, William J ^c  

^a Methodist Hospital Omaha   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Depression; Head and neck cancer; Major depressive disorder; Mouth cancer; Throat cancer; Treatment of depression

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; FLUOXETINE; INTERFERON; MIRTAZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; STEROID; VENLAFAXINE;

ANEMIA; ANXIETY; CANCER PAIN; CAUSAL ATTRIBUTION; CLINICAL TRIAL; CONSULTATION; DEPRESSION; ELECTROCONVULSIVE THERAPY; EMOTIONAL STRESS; FAMILY HISTORY; HAMILTON SCALE; HEAD AND NECK CANCER; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NONHUMAN; PATIENT INFORMATION; PATIENT SATISFACTION; PERSONALITY; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL SUPPORT; SUICIDAL IDEATION; WEIGHT REDUCTION; XEROSTOMIA;

ALCOHOL DRINKING; ANTIDEPRESSIVE AGENTS; ATTITUDE TO DEATH; ATTITUDE TO HEALTH; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERPERSONAL RELATIONS; MALE; PAIN; PSYCHOTHERAPY; QUALITY OF LIFE; RISK; SMOKING; SOCIAL SUPPORT; SUICIDE;

EID: 70349506343     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry. 1990;51:Suppl 7:1217.
2. Mermelstein HT, Lesko L. Depression in patients with cancer. Psycho-Oncology. 1992;1:199-215.
3. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol. 1997;33:189-196.
4. Hammerlid E, Ahlner-Elmqvist M, Bjordal K, et al. A prospective multicentre study in Sweden and Norway of mental distress and psychiatric morbidity in head and neck cancer patients. Br J Cancer. 1999;80:766-774.
5. Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer - a longitudinal study. Head Neck. 2001;23:113-125.
6. Sehlen S, Lenk M, Herschbach P, Aydemir U, Dellian M, Schymura B, Hollenhorst H, Duhmke E. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck. 2003;25:1004-1018.
7. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Arch Gen Psychiatry. 1995;52:89-97.
8. Frampton M. Psychologic distress in patients with head and neck cancer: review. Br J Oral Maxillofacial Surg. 2001;39:67-70.
9. Morton RP, Davies ADM, Baker J, Baker GA, Stell PM. Quality of life in treated head and neck cancer patients: a preliminary report. Clin Otolaryngology. 1984;15:61-69.
10. Baile WF, Gilbertini M, Scott L, Endicott J. Depression and tumor stage in cancer of the head and neck. Psycho-Oncology. 1992;1:15-24.
11. Lydiatt WM, Denman D, McNeilly DP, Puumula SE, Burke WJ. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(5):528-535
12. Kugaya A, Akechi T, Okamura H, Mikami I, Uchitomi Y. Correlates of depressed mood in ambulatory head and neck cancer patients. Psycho-Oncology. 1999;8:494-499.
13. Kugaya A, Akechi T, Okuyama T, Nakano T, Mikami I, Okamura H, Uchitomi Y. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer. 2000;88:2817-2823.
14. De Leeuw JRJ, de Graeff A, Ros WJ, Blijham GH, Hordijk G-J, Winnubst JAM. Prediction of depressive symptomatology after treatment of head and neck cancer: the influence of pre-treatment physical and depressive symptoms, coping, and social support. Head & Neck. 2000; 22:799-807.
15. Gritz ER, Carmack CL, de Moor CL, Coscarelli A, Schacherer CW, Meyers EG, Abemayor E. First year after head and neck cancer: quality of life. J Clin Oncol. 1999;17:352-360.
16. D'Antonio LL, Long SA, Zimmerman GJ, Peterman AH, Petti GH, Chonkich GD. Relationship between quality of life and depression in patients with head and neck cancer. Laryngoscope. 1998;108:806-811.
17. Petty F, Kramer G, Wilson L. Prevention of learned helplessness: in vivo correlation with cortical serotonin. Pharmacol Biochem Behav. 1992;43(2):361-367.
18. De Graeff A, de Leeuw JRJ, Ros WGJ, Hordijk GJ, Blijham GH, Winnubst JAM. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000;110:98-106.
19. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;4:374-383.
20. Irwin M, Patterson T, Smith TL, Caldwell C, Brown SA, Gillin JC, Grant I. Reduction of immune function in life stress and depression. Biol Psychiatry. 1990;27:22-30.
21. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
22. Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999;45:833-9.
23. Musselman DL, Lawson DH, Gumnick JF. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med. 2001;344: 961-966.
24. Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry. 2006;67:1760-1766.
25. Frank MG, Hendricks S, Burke WJ, Johnson DR: Clinical response augments NK cell activity independent of treatment modality: A randomized double-blind placebo controlled antidepressant trial. Psychologic Medicine. 2004;34:491-498.
26. Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry. 2003;60:100-103.
27. Schleifer SJ, Keller SE, Bond RN, Cohen J, Stein M. Major depressive disorder and immunity: role of age, sex, severity, and hospitalization. Arch Gen Psychiatry. 1989;46:81-87.
28. Andreoli AV, Keller SE, Rabaeus M, Marin P, Bartlett JA, Taban C. Depression and immunity: age, severity, and clinical course. Brain Behav Immun. 1993;7: 279-292.
29. Evans DL, Folds JD, Petitto JM, Golden RN, Pedersen CA, Corrigan M, Gilmore JH, Silva SG, Quade D, Ozer H. Circulating natural killer cell phenotypes in men and women with major depression. Arch Gen Psychiatry. 1992;49:388-395.
30. Jung W, Irwin M. Reduction of natural killer cytotoxic activity in major depression: interaction between depression and cigarette smoking. Psychosom Med. 1999;61:263-270.
31. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326-1327.
32. Archer J, Hutchison I, Korszun. Mood and malignancy: head and neck cancer and depression. J Oral Pathol Med. 2008;37:255-270.
33. Lazure K, Lydiatt WM, Burke WJ. An association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck. In press.
34. Yousaf U, Christensen ML, Engholm G, Storm HH. Suicides among Danish cancer patients 1971-1999. British J Cancer. 2005;92:995-1000.
35. Hem E, Loge JH, Haldorsen T, Ekeberg O. Suicide risk in cancer patients from 1960 to 1999. J Clin Oncol. 2004;22:4209-4216.
36. Misono S, Weiss NS Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. J Clin Oncol. 2008;26:705-4707.
37. Farberow NL, Ganzler S, Cutter F, et al. An eight year survey of hospital suicides. Life-threatening Behavior. 1971;1:184-201.
38. Mann JJ, Apter A, Bertolote S, Beautrais A, Currier D, Haas A, et al. Suicide prevention strategies. JAMA. 2005;294:2064-2074.
39. Llewellyn CD, McGurk M, Weinman J. Are psycho-social and behavioural factors related to health related-quality of life in patients with head and neck cancer? A systematic review. Oral Oncology. 2005;41:440-454.
40. Karnell LH, Christensen AJ, Rosenthal EL, Magnuson JS, Funk GF. Influence of social support on health-related quality of life outcomes in head and neck cancer. Head Neck. 2007;29:43-46.
41. Lydiatt WM, Johnson PJ. Cancers of the mouth and throat: a patients' guide to treatment. Omaha, NE: Addicus Books Inc; 2001.
42. Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alchohol, and depression intervention for head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 2006;15:2203-2208.
43. Duffy SA, Ronis DL, Valenstein M, et al. Depressive symptoms, smoking, drinking, and quality of life among head and neck cancer patients. Psychosomatics. 2007;48:142-148.
44. Mehanna HM, Morton RP. Does quality of life predict long-term survival in patients with head and neck cancer? Arch Otolaryngol Head Neck Surg. 2006;132:27-31.
45. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral Sexual Behaviors Associated with Prevalent Oral Human Papillomavirus Infection. J Infect Dis. 2009;199:1263-1269.
46. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:401-420.
47. Sollner W, DeVries A, Steixner E, et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counseling? British J Cancer. 2001;84:179-185.
48. Mahoney J, Drinka TJK, Abler R, et al. Screening for depression: single question versus GDS. J Am Geriatr Soc. 1994;9:1006-1008.
49. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69-77.
50. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDSC), and self-report (QIDSSR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-583.
51. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493-501.
52. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDSC) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73-82.
53. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. Am J Psychiatry. 2006;163:28-40.
54. Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: bio-psychologic interaction and treatment considerations. J Clin Psychiatry. 1999;60: Suppl 4:40-55.
55. Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, McHugh G, Walker A, Sharpe M. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet. 2008;372:40-48.
56. Chaturvedi PR, Maguire P, Hopwood P. Antidepressant medication in cancer patients. Psycho-Oncology. 1994;3:57-60.
57. Stockler, MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomized trial. Lancet Oncol. 2007;8:603-612.
58. Fisch MJ, Loehrer RJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21:1937-1943.